Luca Issi
Stock Analyst at RBC Capital
(1.52)
# 2,371
Out of 4,479 analysts
111
Total ratings
40%
Success rate
-10.66%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $250 → $265 | $247.61 | +7.02% | 17 | Jun 27, 2024 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Outperform | $40 | $20.58 | +94.36% | 4 | Jun 26, 2024 | |
| MRNA Moderna | Maintains: Outperform | $135 → $160 | $117.07 | +36.67% | 8 | Jun 3, 2024 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Outperform | $77 | $40.96 | +87.99% | 1 | Apr 22, 2024 | |
| BLUE bluebird bio | Reiterates: Sector Perform | $8 | $0.92 | +766.65% | 3 | Mar 27, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $70 → $90 | $33.11 | +171.82% | 3 | Mar 27, 2024 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $30 → $20 | $6.84 | +192.40% | 4 | Mar 19, 2024 | |
| MGTX MeiraGTx Holdings | Reiterates: Outperform | $11 | $3.94 | +179.19% | 3 | Mar 15, 2024 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $2.16 | +362.96% | 6 | Mar 15, 2024 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.32 | +524.80% | 5 | Mar 14, 2024 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $22 → $24 | $14.02 | +71.18% | 2 | Mar 12, 2024 | |
| CRBU Caribou Biosciences | Reiterates: Outperform | $19 | $1.60 | +1,087.50% | 4 | Mar 12, 2024 | |
| RGNX REGENXBIO | Upgrades: Outperform | $20 → $35 | $10.75 | +225.58% | 6 | Mar 8, 2024 | |
| WVE Wave Life Sciences | Reiterates: Sector Perform | $5 | $5.22 | -4.21% | 3 | Mar 7, 2024 | |
| VERV Verve Therapeutics | Reiterates: Outperform | $35 | $5.00 | +600.00% | 4 | Feb 28, 2024 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $27 → $35 | $22.57 | +55.07% | 3 | Feb 28, 2024 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Sector Perform | $100 | $82.22 | +21.62% | 6 | Feb 23, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $57 → $66 | $53.12 | +24.26% | 8 | Feb 22, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Outperform | $50 | $25.22 | +98.26% | 6 | Feb 7, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $65 → $70 | $45.14 | +55.07% | 5 | Jan 26, 2024 | |
| QURE uniQure | Reiterates: Outperform | $28 | $4.01 | +598.25% | 3 | Jan 16, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $80 → $70 | $22.15 | +216.03% | 2 | Nov 10, 2023 | |
| EDIT Editas Medicine | Maintains: Sector Perform | $7 → $8 | $4.54 | +76.21% | 5 | May 8, 2023 |
Alnylam Pharmaceuticals
Jun 27, 2024
Maintains: Outperform
Price Target: $250 → $265
Current: $247.61
Upside: +7.02%
4D Molecular Therapeutics
Jun 26, 2024
Reiterates: Outperform
Price Target: $40
Current: $20.58
Upside: +94.36%
Moderna
Jun 3, 2024
Maintains: Outperform
Price Target: $135 → $160
Current: $117.07
Upside: +36.67%
Ultragenyx Pharmaceutical
Apr 22, 2024
Initiates: Outperform
Price Target: $77
Current: $40.96
Upside: +87.99%
bluebird bio
Mar 27, 2024
Reiterates: Sector Perform
Price Target: $8
Current: $0.92
Upside: +766.65%
Korro Bio
Mar 27, 2024
Maintains: Outperform
Price Target: $70 → $90
Current: $33.11
Upside: +171.82%
Adverum Biotechnologies
Mar 19, 2024
Maintains: Sector Perform
Price Target: $30 → $20
Current: $6.84
Upside: +192.40%
MeiraGTx Holdings
Mar 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.94
Upside: +179.19%
Allogene Therapeutics
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.16
Upside: +362.96%
Sangamo Therapeutics
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $0.32
Upside: +524.80%
Lexeo Therapeutics
Mar 12, 2024
Maintains: Outperform
Price Target: $22 → $24
Current: $14.02
Upside: +71.18%
Caribou Biosciences
Mar 12, 2024
Reiterates: Outperform
Price Target: $19
Current: $1.60
Upside: +1,087.50%
REGENXBIO
Mar 8, 2024
Upgrades: Outperform
Price Target: $20 → $35
Current: $10.75
Upside: +225.58%
Wave Life Sciences
Mar 7, 2024
Reiterates: Sector Perform
Price Target: $5
Current: $5.22
Upside: -4.21%
Verve Therapeutics
Feb 28, 2024
Reiterates: Outperform
Price Target: $35
Current: $5.00
Upside: +600.00%
Beam Therapeutics
Feb 28, 2024
Maintains: Sector Perform
Price Target: $27 → $35
Current: $22.57
Upside: +55.07%
BioMarin Pharmaceutical
Feb 23, 2024
Reiterates: Sector Perform
Price Target: $100
Current: $82.22
Upside: +21.62%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Sector Perform
Price Target: $57 → $66
Current: $53.12
Upside: +24.26%
Arrowhead Pharmaceuticals
Feb 7, 2024
Reiterates: Outperform
Price Target: $50
Current: $25.22
Upside: +98.26%
Ionis Pharmaceuticals
Jan 26, 2024
Maintains: Outperform
Price Target: $65 → $70
Current: $45.14
Upside: +55.07%
uniQure
Jan 16, 2024
Reiterates: Outperform
Price Target: $28
Current: $4.01
Upside: +598.25%
Intellia Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $80 → $70
Current: $22.15
Upside: +216.03%
Editas Medicine
May 8, 2023
Maintains: Sector Perform
Price Target: $7 → $8
Current: $4.54
Upside: +76.21%